IN8bio, Inc.
INAB
Rank in Stocks
#28976
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase,... IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
Share Price
$0.9401
Last synced: 2026-11-09
Market Cap
$9.27M
Change (1 day)
1.47%
Change (1 year)
-44.04%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade IN8bio, Inc. (INAB)
Category
Healthcare
EPS for IN8bio, Inc. (INAB)
EPS as of September 2026 TTM: $-1.26
According to IN8bio, Inc.'s latest financial reports, its current EPS (TTM) is $-1.26. At the end of 2025 the company had an EPS of $-4.44, an increase over its 2024 EPS of $-17.05.
EPS history for IN8bio, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.26 | -71.62% |
| 2025 | $-4.44 | -73.96% |
| 2024 | $-17.05 | -43.43% |
| 2023 | $-30.14 | -26.15% |
| 2022 | $-40.81 | 74.33% |
| 2021 | $-23.41 | 46.04% |
| 2020 | $-16.03 | 75.00% |
| 2019 | $-9.16 | 135.48% |
| 2018 | $-3.89 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,342.86% |
US
|
|
| $-7.07 | 461.11% |
US
|
|
| $-5.29 | 319.84% |
AU
|
|
| $12.88 | -1,122.23% |
BE
|
|
| $21.56 | -1,811.11% |
NL
|
Questions about IN8bio, Inc.'s earnings per share (EPS)
What is IN8bio, Inc.'s earnings per share (EPS)?
IN8bio, Inc.'s earnings per share (EPS) over the last twelve months is $-1.26, as of Sep 2026.
What was IN8bio, Inc.'s earnings per share (EPS) in 2025?
In 2025, IN8bio, Inc.'s earnings per share (EPS) was $-4.44, compared with $-17.05 in 2024.
How has IN8bio, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, IN8bio, Inc.'s earnings per share (EPS) was highest in 2025 ($-4.44) and lowest in 2022 ($-40.81).
How does IN8bio, Inc.'s earnings per share (EPS) compare with similar companies?
IN8bio, Inc.'s earnings per share (EPS) ($-1.26) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.